Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2025-

Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers

Sarepta Therapeutics is meeting with the FDA in June to discuss expanding the use of its Duchenne muscular dystrophy gene therapy to patients younger than 4 years old. The outcome could serve as a litmus ...